We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

PET-CT Based Radiotherapy in Esophageal Cancer Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01156831
First Posted: July 5, 2010
Last Update Posted: December 8, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Maastricht Radiation Oncology
July 2, 2010
July 5, 2010
December 8, 2014
November 2007
May 2011   (Final data collection date for primary outcome measure)
Locoregional control [ Time Frame: 2 years and 5 years ]
Same as current
Complete list of historical versions of study NCT01156831 on ClinicalTrials.gov Archive Site
  • Overall Survival [ Time Frame: 2 years and 5 years ]
  • Disease Free survival [ Time Frame: 2 years and 5 years ]
  • Tumor regression grade [ Time Frame: At the time of surgery ]
    Tumor regression grade at time of surgery evaluated by pathologist.
Same as current
Not Provided
Not Provided
 
PET-CT Based Radiotherapy in Esophageal Cancer Patients
Consequences of Positron-Emission-Tomography/Computed Tomography (PET/CT) Based Radiotherapy Treatment Planning for Clinical Outcome in Esophageal Cancer Patients
The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients.
The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Primary Care Clinic
Esophageal Neoplasms
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
115
May 2013
May 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically proven adenocarcinoma or squamous cell carcinoma of the esophagus
  • Local curable disease able to undergo Chemoradiotherapy.

Exclusion Criteria:

  • Metastasized disease.
  • Previous or concurrent malignancies.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
 
NCT01156831
09-18-12/08
Yes
Not Provided
Not Provided
Maastricht Radiation Oncology
Maastricht Radiation Oncology
Not Provided
Principal Investigator: Guido Lammering, MD PhD Radiation Oncology, Maastro Clinic
Principal Investigator: Meindert Sosef, MD PhD Atrium Hospital Heerlen
Maastricht Radiation Oncology
December 2014